Grifols SA
Research Grifols SA (GRFS) on Bullrun: valuation model: 26.3% undervalued, market cap USD 1.89B, P/E 10.4, dividend yield 2.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGRFS
- ExchangeNASDAQ
- CountrySpain
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal26.3% undervalued
- Market capUSD 1.89B
- P/E10.4
- Dividend yield2.3%
- Financial periodQ1 2026
- RevenueUSD 7.44B
- Net incomeUSD 73.00M
- Free cash flowUSD 20.00M
- Gross margin8.3%
Valuation Snapshot
Bullrun's latest valuation model marks Grifols SA as 26.3% undervalued; latest market cap is USD 1.89B; P/E is 10.4; dividend yield is 2.3%.
About Grifols SA
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas;
Frequently asked questions
Is Grifols SA overvalued or undervalued?
Bullrun's valuation model currently marks Grifols SA as 26.3% undervalued.
What is Grifols SA's market cap?
Grifols SA's market capitalization is USD 1.89B.
What is Grifols SA's P/E ratio?
Grifols SA's price-to-earnings (P/E) ratio is 10.4.
Does Grifols SA pay a dividend?
Grifols SA has a dividend yield of 2.3%.
What does Grifols SA do?
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.